Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. DTCA/I, consumer secondary audience
  4. 174 - Dear PAAB: Does inclusion of a product Name, and its associated DIN, adhere to name/price/quantity guidelines in c.01.044? Does package size (i.e. weekly, monthly and number of tablets) meet the regulations for quantity? Many thanks.
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

174 - Dear PAAB: Does inclusion of a product Name, and its associated DIN, adhere to name/price/quantity guidelines in c.01.044? Does package size (i.e. weekly, monthly and number of tablets) meet the regulations for quantity? Many thanks.

Scheduled Pinned Locked Moved DTCA/I, consumer secondary audience
1 Posts 1 Posters 493 Views 1 Watching
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Jennifer CarrollJ Online
    Jennifer CarrollJ Online
    Jennifer Carroll
    wrote on last edited by
    #1

    Including the DIN in a reminder ad for a prescription drug directed to consumers does not adhere to the letter and spirit of Section C.01.044 of the Food and Drug Regulations. As you may be aware, reminder ads are acceptable provided that there is no allusion or link to the therapeutic indication of the advertised product. However, as it is often the case with reminder ad campaigns, market authorization holders set up a branded prescription drug Web site where patients who have been prescribed the prescription drug can enter the DIN in order to get access to the full product information. This practice has been deemed acceptable by Health Canada as it acts as a mechanism to restrict access to patients, and not the entire general public. Therefore, in such a scenario, providing the DIN in a reminder ad would likely constitute a direct-to-consumer advertising in contravention of Section C.01.044. With respect to your question about package size, we would suggest that you restrict the quantity claim such that it relates to the number of units provided for the price, as this will provide accurate information as to the unit price. If your question is more related to product package representations, we invite you to consult the Health Canada policy entitled "Product Package Representations in Branded Prescription Drug Reminder Ads Directed to Consumers" available at: http://www.hc-sc.gc.ca/dhp-mps/advert-publicit/pol/notice-avis_reminder-rappel-eng.php.

    1 Reply Last reply
    0
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • Users
    • Groups